Cardioprotective Effects and in-silico Antioxidant Mechanism of L-Ergothioneine in Experimental Type-2 Diabetic Rats

Abstract

Background: Diabetic cardiotoxicity is commonly associated with oxidative injury, inflammation, and endothelial dysfunction. L-ergothioneine (L-egt), a diet-derived amino acid, has been reported to decrease mortality and risk of cardiovascular injury, provides cytoprotection to tissues exposed to oxidative damage, and prevents diabetes-induced perturbation. Objective: This study investigated the cardioprotective effects of L-egt on diabetes-induced cardiovascular injuries and its probable mechanism of action. Methods: Twenty-four male Sprague-Dawley rats were divided into non-diabetic (n=6) and diabetic groups (n=18). Six weeks after the induction of diabetes, the diabetic rats were divided into three groups (n=6) and administered distilled water, L-egt (35mg/kg), and losartan (20mg/kg) by oral gavage for six weeks. Blood glucose and mean arterial pressure (MAP) were recorded pre-and post-treatment, while biochemical, ELISA, and Rt-PCR analyses were conducted to determine inflammatory, injury-related and antioxidant biomarkers in cardiac tissue after euthanasia. Also, an in-silico study, including docking and molecular dynamic simulations of L-egt toward the Keap1-Nrf2 protein complex, was done to provide a basis for the molecular antioxidant mechanism of L-egt. Results: Administration of L-egt to diabetic animals reduced serum triglyceride, water intake, MAP, biomarkers of cardiac injury (CK-MB, LDH), lipid peroxidation, and inflammation. Also, L-egt increased body weight, antioxidant enzymes, upregulated Nrf2, HO-1, NQO1 expression, and decreased Keap1 expression. The in-silico study showed that L-egt inhibits Keap1-Nrf2 complex by binding to the active site of Nrf2 protein, thereby preventing its degradation. Conclusion: L-egt protects against diabetes-induced cardiovascular injury via the upregulation of Keap1-Nrf2 pathway and its downstream cytoprotective antioxidants.

Protective Mechanism Pathway of Swietenia macrophylla Extract Nanoparticles against Cardiac Cell Damage in Diabetic Rats

“…Many studies have used STZ to model diabetes cardiomyopathy in rats [ 15 , 16 , 17 ]. In this diabetic cardiomyopathy rat model, elevated ROS levels are presented with higher MDA levels and decreased antioxidant—such as SOD, GPx and Nrf2—expression, which then induced cardiac cell damage [ 1 , 5 , 7 ].…”

Ergothioneine supplementation in people with metabolic syndrome (ErgMS): protocol for a randomised, double-blind, placebo-controlled pilot study

“…Similarly, several of the inflammatory markers we intend to measure have been shown to be modulated in protective fashion by ergothioneine in preclinical models; e.g. TNF-α [35], Nrf2 [36] and NOX4 [34]. In the context of COVID-19, a possible factor affecting measures of inflammation might be vaccination timing, and this information will be collected from participants and examined as a potential confounder.…”

Ergothioneine and its congeners: anti-ageing mechanisms and pharmacophore biosynthesis

“…Additionally, it has also been revealed that NRF2 translocation was mediated by PI3K/AKT and PKC signaling pathways ( Hseu et al, 2015 , 2020 ). An in silico work indicated that Ergothioneine is an allosteric effector of NRF2, suggesting a direct interaction of Ergothioneine with NRF2 ( Dare et al, 2022 ). Alternatively, Ergothioneine influences the KEAP1–NRF2 pathway possibly via its interaction with KEAP1, a thiol-rich protein.…”